アレルギー性疾患の新治療剤M-S抗原に関する研究
スポンサーリンク
概要
- 論文の詳細を見る
It is well known that production of tolerance in previously immunized animals has been achieved only after injection of very large doses of antigen. One reason for this difficulty may be that circulating antibody may combine with a given dose of antigen and form antigen-antibody complexes which are rapidly removed from the circulation. It also seems likely that successful clinical hyposensitization of atopic patients may be analogous to the production of tolerance in previously immunized subjects. In an attempt to follow up the fate of such complexes after their removal from the circulation, I have searched for urinary components of atopic patients which are capable of causing some serological reactions with their sera. I have found out an urinary component, named MS-antigen, which can react with patients' sera and cause precipitation reaction. It is also capable of producing precipitin of high titers in animals and humans when it is injected at proper intervals. It has neither skin sensitizing properties nor allergy provoking effect, however, clinical hyposensitization can be successfully achieved in various atopic patients by repeated injection of auto-MS-antigen. This substance is non-toxic and can be used quite safely for clinical purposes. Over 100 atopic patients with asthma bronchiale, acute and chronic ulticaria, allergic rhinitis, atopic dermatitis etc have been treated in this wasy with significantly favorable results. Here I will report on the pattern of precipitin production in animals and humans, the relationship between titers of precipitin production in animals and humans, the relationship between titers of precipitin and patients' clinical course, serological typing of MS-antigens and the favorable results obtained from clinical application of MS-antigen
- 日本アレルギー学会の論文
- 1967-04-30
著者
関連論文
- 270 アレルギー患者尿由来のPolypeptide(MS-Antigen)の筋肉投与によるIgE抗体抑制作用(RAST)と臨床成績
- 89.MS抗原による「ア」性疾患の治療成績と各種器官におよぼす影響(抗原)
- アレルギー性疾患の新治療剤 MS 抗原に関する臨床的研究
- 24. 気管支喘息の新治療剤 MS-Antigen (Atopion)による治療について(II喘息)(第16回日本アレルギー学会総会)
- 57.アレルギー性疾患の新治療剤M-S Antigen(Atopion)に関する研究(I. 抗アレルギー作用に関するもの)(第16回日本アレルギー学会総会)
- 158. Schwzrtman型壊死反応によるマウスの腫瘍組織に対する移植免疫の研究(シュワルツマン反応)
- 74.MS抗原によるアレルギー性疾患の診断的研究(アレルギー・免疫学的診断法)
- 101. MS抗原のアレルギー性反応抑制作用とMS抗原治療によるアレルギー性疾患の予後(喘息(V))
- 101.MS抗原治療によるアレルギー性疾患の予後とMS抗原のアレルギー性反応の抑制作用(喘息(V))
- 9)アレルギー性疾患の新治療剤multivalent-MS抗原による治療成績
- アレルギー性疾患の新治療剤M-S抗原に関する研究
- 58.アレルギー性疾患 (鼻炎及び皮膚疾患)の MS-Antigen (Atpion) による治療成績(I. 抗アレルギー作用に関するもの)(第16回日本アレルギー学会総会)
- ブドウ球菌類似の薬剤耐性球菌に関する研究 : 第1報 Micrococcus fasteus n. sp. Soeda et al. (1964)の性状について
- 耐性ブドウ球菌トキソイドの治療効果判定に関する研究
- X線照射による白血球減少家兎に対するanti-leucopenic action
- 耐性ブドウ球菌に関する研究